The UK government has confirmed that mechanisms will be in place from 1 January 2021 allowing the medicines regulator, the MHRA, to issue national conditional marketing authorizations (CMAs) and to approve products under exceptional circumstances, based on the same eligibility criteria as the existing EU schemes.
The UK is having to change its regulations because when the Brexit transition period ends on 31 December, the MHRA will become a fully freestanding regulator issuing its own marketing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?